Skip to main content

Perioperative Anti-platelet Therapy for Patients undergoing Carotid Endarterectomy

CBE ID
0465
Endorsement Status
E&M Committee Rationale/Justification

Steward no longer seeking to maintain endorsement

1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

Percentage of patients undergoing carotid endarterectomy (CEA) who are taking an anti-platelet agent (aspirin or clopidogrel or equivilant such as aggrenox/tiglacor etc) within 48 hours prior to surgery and are prescribed this medication at hospital discharge following surgery

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.14 Numerator

      Patients over age 18 undergoing carotid endarterectomy who received anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists within 48 hours prior to the initiation of surgery AND are prescribed this medication at hospital discharge following surgery.

      1.15 Denominator

      Patients over age 18 undergoing carotid endarterectomy.

      Exclusions

      Patients with known intolerance to anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists, or those on heparin or other intravenous anti-coagulants; patients with active bleeding or undergoing urgent or emergent operations or endarterectomy combined with cardiac surgery. Patients with known intolerance to anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists, or those on or other intravenous anti-coagulants; patients with active bleeding or undergoing urgent or emergent operations or endarterectomy combined with cardiac surgery.

      Most Recent Endorsement Activity
      Endorsed Surgery Endorsement Maintenance Project 2014
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      Society for Vascular Surgery
      Steward POC email
      Jill_Rathbun@galileogrp.com
                Public Comments